Cook Anne Marie

SEC source: 0001193125-26-048881 · ownership.xml · nonDerivative · entry 2

Cook Anne Marie · CIK 0001320559 · Chief Legal Off. & Corp. Sec.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,660

F3 · kind: Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.

SEC source: 0001193125-26-048881 · ownership.xml · nonDerivative · entry 1

Cook Anne Marie · CIK 0001320559 · Chief Legal Off. & Corp. Sec.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,195

F1 · shares: Represents shares issued upon vesting of performance stock units granted to the reporting person on June 23, 2025 based on the achievement of performance criteria determined to be satisfied on February 10, 2026.

F2 · balance_after: Includes 1,722 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2026.

SEC source: 0001193125-26-001125 · ownership.xml · derivative · entry 2

Cook Anne Marie · CIK 0001320559 · Chief Legal Off. & Corp. Sec.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,878

Underlying: Common Stock · 67,878 shares

Expires 2036-01-01

F2 · derivative.exercise_date: 1/48th of the total number of shares of common stock subject to the option vest monthly following the Vesting Commencement Date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

SEC source: 0001193125-26-001125 · ownership.xml · nonDerivative · entry 1

Cook Anne Marie · CIK 0001320559 · Chief Legal Off. & Corp. Sec.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,012

F1 · shares: Represents restricted stock units ("RSUs") granted on January 2, 2026. 1/3 of the total number of RSUs granted vest on each of the first three anniversaries of January 2, 2026, the vesting commencement date (the "Vesting Commencement Date"), subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

SEC source: 0001193125-25-327131 · ownership.xml · nonDerivative · entry 2

Cook Anne Marie · CIK 0001320559 · Chief Legal Off. & Corp. Sec.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,667

F2 · kind: Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.

SEC source: 0001193125-25-327131 · ownership.xml · nonDerivative · entry 1

Cook Anne Marie · CIK 0001320559 · Chief Legal Off. & Corp. Sec.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,370

F1 · shares: Represents shares issued upon vesting of performance stock units granted to the reporting person on June 23, 2025 based on the achievement of performance criteria determined to be satisfied on December 17, 2025.

SEC source: 0000950170-25-089513 · ownership.xml · derivative · entry 1

Cook Anne Marie · CIK 0001320559 · Chief Legal Off. & Corp. Sec.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 210,000

Underlying: Common Stock · 210,000 shares

Expires 2035-06-22

F1 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on June 23, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the Reporting Person's continuous service to the Issuer on the applicable vesting dates.

SEC source: 0001562180-24-006087 · primarydocument.xml · nonDerivative · entry 2

Cook Anne Marie · CIK 0001320559 · SVP, GC & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,040

SEC source: 0001562180-24-006087 · primarydocument.xml · nonDerivative · entry 1

Cook Anne Marie · CIK 0001320559 · SVP, GC & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,543

F1 · shares: On February 13, 2024, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 33,750 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on August 5, 2024, resulting in the vesting of the PSUs as to 13,500 shares.

F2 · balance_after: Reflects beneficial ownership balance which includes 1,112 shares purchased on June 28, 2024 under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan.

SEC source: 0001562180-24-001335 · primarydocument.xml · derivative · entry 2

Cook Anne Marie · CIK 0001320559 · SVP, GC & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2034-02-13

F3 · derivative.exercise_date: The securities awarded on February 13, 2024 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 5,625 shares of common stock shall vest on the one year anniversary of February 13, 2024, with 16,875 shares vesting in 36 equal monthly installments thereafter.

SEC source: 0001562180-24-001335 · primarydocument.xml · nonDerivative · entry 1

Cook Anne Marie · CIK 0001320559 · SVP, GC & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,181

F1 · shares: Consists of shares of common stock issuable under 11,250 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on February 13, 2025.

F2 · balance_after: Reflects beneficial ownership balance which includes 215 shares purchased on December 29, 2023 under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan.

SEC source: 0001562180-23-007978 · primarydocument.xml · nonDerivative · entry 2

Cook Anne Marie · CIK 0001320559 · SVP, GC & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,716

SEC source: 0001562180-23-007978 · primarydocument.xml · nonDerivative · entry 1

Cook Anne Marie · CIK 0001320559 · SVP, GC & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,890

F1 · shares: On March 25, 2020, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 10,000 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on November 28, 2023, resulting in the vesting of the PSUs as to 4,000 shares.

F2 · balance_after: Reflects beneficial ownership balance which includes 392 shares purchased on June 30, 2023 under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan.

SEC source: 0001562180-23-001423 · primarydocument.xml · derivative · entry 1

Cook Anne Marie · CIK 0001320559 · SVP, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2033-02-13

F1 · derivative.exercise_date: The securities awarded on February 13, 2023 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 4,750 shares of common stock shall vest on the one year anniversary of February 13, 2023, with 14,250 shares vesting in 36 equal monthly installments thereafter.

SEC source: 0001562180-23-001080 · primarydocument.xml · nonDerivative · entry 2

Cook Anne Marie · CIK 0001320559 · SVP, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,498

SEC source: 0001562180-23-001080 · primarydocument.xml · nonDerivative · entry 1

Cook Anne Marie · CIK 0001320559 · SVP, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,478

F1 · shares: On February 10, 2021, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 9,500 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on February 3, 2023, resulting in the vesting of the PSUs as to 2,850 shares.

F2 · balance_after: Reflects beneficial ownership balance which includes 221 shares purchased on June 30, 2022 and 432 shares purchased on December 31, 2022, each under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan.

SEC source: 0001562180-22-001474 · primarydocument.xml · derivative · entry 1

Cook Anne Marie · CIK 0001320559 · SVP, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,200

Underlying: Common Stock · 15,200 shares

Expires 2032-02-11

F1 · derivative.exercise_date: The securities awarded on February 11, 2022 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 3,800 shares of common stock shall vest on the one year anniversary of February 11, 2022, with 11,400 shares vesting in 36 equal monthly installments thereafter.

SEC source: 0001562180-21-006598 · primarydocument.xml · nonDerivative · entry 2

Cook Anne Marie · CIK 0001320559 · SVP, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,894

SEC source: 0001562180-21-006598 · primarydocument.xml · nonDerivative · entry 1

Cook Anne Marie · CIK 0001320559 · SVP, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,010

F1 · shares: On February 13, 2019, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 9,500 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on October 19, 2021, resulting in the vesting of the PSUs as to 3,800 shares.

F2 · balance_after: Reflects beneficial ownership balance which includes 237 shares purchased on June 30, 2021 under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan.

SEC source: 0001562180-21-004341 · primarydocument.xml · nonDerivative · entry 2

Cook Anne Marie · CIK 0001320559 · SVP, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,973

F2 · balance_after: Reflects beneficial ownership balance which includes 313 shares purchased on June 30, 2020 under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan (the "ESPP") and 48 ESPP shares purchased on December 31, 2020 under the ESPP.

SEC source: 0001562180-21-004341 · primarydocument.xml · nonDerivative · entry 1

Cook Anne Marie · CIK 0001320559 · SVP, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,117

F1 · shares: On March 25, 2020, the reporting person was granted Performance Stock Units (PSU) to acquire a total of 10,000 shares of common stock. The PSU vests upon the achievement of certain milestones, one of which was met on June 15, 2021, resulting in the vesting of the PSU as to 4,000 shares.

F2 · balance_after: Reflects beneficial ownership balance which includes 313 shares purchased on June 30, 2020 under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan (the "ESPP") and 48 ESPP shares purchased on December 31, 2020 under the ESPP.

SEC source: 0001562180-21-001125 · primarydocument.xml · derivative · entry 1

Cook Anne Marie · CIK 0001320559 · SVP, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2031-02-10

F1 · derivative.exercise_date: The securities awarded on February 10, 2021 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 4,750 shares of common stock shall vest on the one year anniversary of February 10, 2021, with 14,250 shares vesting in 36 equal monthly installments thereafter.

SEC source: 0001562180-20-003222 · primarydocument.xml · derivative · entry 1

Cook Anne Marie · CIK 0001320559 · SVP, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,450

Underlying: Common Stock · 9,450 shares

Expires 2030-04-28

F1 · derivative.exercise_date: The securities awarded on April 28, 2020 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. 25% of the shares of common stock underlying this stock option award will vest on April 28, 2021, and the remaining 75% of the shares of common stock underlying this stock option award will vest on April 28, 2022, subject, in each case, to the Reporting Person's continued employment with the Issuer on each of the applicable vesting dates.

SEC source: 0001562180-20-001243 · primarydocument.xml · derivative · entry 1

Cook Anne Marie · CIK 0001320559 · SVP, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2030-02-12

F1 · derivative.exercise_date: The securities awarded on February 12, 2020 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 5,000 shares of common stock shall vest on the one year anniversary of February 12, 2020, with 15,000 shares vesting in 36 equal monthly installments thereafter.

SEC source: 0001562180-19-004088 · primarydocument.xml · nonDerivative · entry 2

Cook Anne Marie · CIK 0001320559 · SVP, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,756

SEC source: 0001562180-19-004088 · primarydocument.xml · nonDerivative · entry 1

Cook Anne Marie · CIK 0001320559 · SVP, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,600

F1 · shares: On February 13, 2019, the reporting person was granted Performance Stock Units (PSU) to acquire a total of 9,500 shares of common stock. The PSU vests upon the achievement of certain milestones, one of which was met on July 25, 2019, resulting in the vesting of the PSU as to 1,900 shares.

SEC source: 0001562180-19-003638 · primarydocument.xml · derivative · entry 1

Cook Anne Marie · CIK 0001320559 · SVP, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,480

Underlying: Common Stock · 9,240 shares

Expires 2027-02-06

F1 · derivative.exercise_date: On February 6, 2017, the reporting person was granted an option to purchase 28,000 shares of common stock. The option vests upon the achievement of certain milestones, one of which was met on June 21, 2019, resulting in the vesting of the option as to 9,240 shares.

SEC source: 0001562180-19-002767 · primarydocument.xml · derivative · entry 5

Cook Anne Marie · CIK 0001320559 · SVP, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,300

Underlying: Common Stock · 700 shares

Expires 2025-09-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F4 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. 27,500 shares vested on September 16, 2016 with the remaining shares vesting in equal monthly installments over the 36 months following September 16, 2016.

SEC source: 0001562180-19-002767 · primarydocument.xml · derivative · entry 4

Cook Anne Marie · CIK 0001320559 · SVP, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2026-02-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · derivative.exercise_date: The securities awarded on February 8, 2016 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 5,000 shares of common stock vested on February 8, 2017, with 15,000 shares vesting in 36 equal monthly installments thereafter. Options to purchase 10,000 shares of common stock shall vest periodically upon the Company reaching certain milestone.

F3 · balance_after: Reflects the balance after 10,000 options were forfeited due to unmet performance condition.

SEC source: 0001562180-19-002767 · primarydocument.xml · nonDerivative · entry 3

Cook Anne Marie · CIK 0001320559 · SVP, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 700

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001562180-19-002767 · primarydocument.xml · nonDerivative · entry 2

Cook Anne Marie · CIK 0001320559 · SVP, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercises reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001562180-19-002767 · primarydocument.xml · nonDerivative · entry 1

Cook Anne Marie · CIK 0001320559 · SVP, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001562180-19-001031 · primarydocument.xml · derivative · entry 1

Cook Anne Marie · CIK 0001320559 · SVP, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2029-02-13

F1 · derivative.exercise_date: The securities awarded on February 13, 2019 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 4,750 shares of common stock shall vest on the one year anniversary of February 13, 2019, with 14,250 shares vesting in 36 equal monthly installments thereafter.

SEC source: 0001562180-18-004911 · primarydocument.xml · derivative · entry 1

Cook Anne Marie · CIK 0001320559 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,240

Underlying: Common Stock · 9,240 shares

Expires 2027-02-06

F1 · derivative.exercise_date: On February 6, 2017, the reporting person was granted an option to purchase 28,000 shares of common stock. The option vests upon the achievement of certain milestones, one of which was met on December 7, 2018, resulting in the vesting of the option as to 9,240 shares.

SEC source: 0001562180-18-001841 · primarydocument.xml · derivative · entry 1

Cook Anne Marie · CIK 0001320559 · Senior VP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,500

Underlying: Common Stock · 31,500 shares

Expires 2028-04-02

F1 · derivative.exercise_date: The securities awarded on 4/2/2018 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 3,938 shares of common stock shall vest on the one year anniversary of the 2/1/2018 Vesting Start Date with 11,812 shares vesting in 36 equal monthly installments thereafter. Options to purchase 15,750 shares of common stock shall vest periodically upon the Company achieving certain milestones..

SEC source: 0001562180-17-000572 · primarydocument.xml · derivative · entry 1

Cook Anne Marie · CIK 0001320559 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,000

Underlying: Common Stock · 56,000 shares

Expires 2027-02-08

F1 · derivative.exercise_date: The securities awarded on 2/06/2017 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 7,000 shares of common stock shall vest on the one year anniversary of the Vesting Start Date with 21,000 shares vesting in 36 equal monthly installments thereafter. Options to purchase 28,000 shares of common stock shall vest periodically upon the Company achieving certain milestones.

SEC source: 0001562180-16-003830 · primarydocument.xml · derivative · entry 1

Cook Anne Marie · CIK 0001320559 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 10,000 shares

Expires 2026-02-28

F1 · balance_after: The securities awarded on 2/08/2016 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 5,000 shares of common stock shall vest on the one year anniversary of the Vesting Start Date with 15,000 shares vesting in 36 equal monthly installments thereafter. Options to purchase 20,000 shares of common stock vest periodically upon the company reaching certain milestone requirements, of which the performance criteria were met with the respect of 10,000 shares.